PCRX
Income statement / Annual
Last year (2023), Pacira BioSciences, Inc.'s total revenue was $674.98 M,
an increase of 1.22% from the previous year.
In 2023, Pacira BioSciences, Inc.'s net income was $41.96 M.
See Pacira BioSciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$674.98 M
|
$666.82 M
|
$541.53 M
|
$420.83 M
|
$421.03 M
|
$337.28 M
|
$286.63 M
|
$276.37 M
|
$249.00 M
|
$197.67 M
|
| Cost of Revenue |
$184.67 M |
$199.30 M |
$140.26 M |
$117.33 M |
$106.71 M |
$86.85 M |
$87.92 M |
$110.10 M |
$71.84 M |
$77.44 M |
| Gross Profit |
$490.31 M |
$467.53 M |
$401.28 M |
$303.50 M |
$314.31 M |
$250.43 M |
$198.72 M |
$166.27 M |
$177.16 M |
$120.23 M |
| Gross Profit Ratio |
0.73 |
0.7 |
0.74 |
0.72 |
0.75 |
0.74 |
0.69 |
0.6 |
0.71 |
0.61 |
| Research and Development
Expenses |
$76.26 M
|
$84.80 M
|
$55.55 M
|
$59.42 M
|
$72.12 M
|
$55.69 M
|
$57.29 M
|
$45.68 M
|
$28.66 M
|
$18.73 M
|
| General & Administrative
Expenses |
$116.40 M
|
$109.52 M
|
$88.32 M
|
$74.83 M
|
$71.12 M
|
$70.16 M
|
$66.69 M
|
$63.40 M
|
$61.31 M
|
$41.65 M
|
| Selling & Marketing
Expenses |
$153.04 M
|
$145.00 M
|
$111.02 M
|
$118.68 M
|
$129.66 M
|
$107.11 M
|
$94.80 M
|
$89.22 M
|
$77.73 M
|
$65.01 M
|
| Selling, General &
Administrative Expenses |
$269.44 M
|
$254.52 M
|
$199.35 M
|
$193.52 M
|
$200.78 M
|
$177.27 M
|
$161.49 M
|
$152.61 M
|
$139.04 M
|
$106.66 M
|
| Other Expenses |
$241.61 M |
$57.29 M |
$13.55 M |
$7.87 M |
$5.70 M |
-$888,000.00 |
$167,000.00 |
-$82,000.00 |
-$165,000.00 |
-$159,000.00 |
| Operating Expenses |
$326.38 M |
$396.60 M |
$268.44 M |
$260.80 M |
$278.60 M |
$232.95 M |
$218.78 M |
$198.29 M |
$167.71 M |
$125.39 M |
| Cost And Expenses |
$587.30 M |
$595.90 M |
$408.70 M |
$378.13 M |
$385.32 M |
$319.80 M |
$306.70 M |
$308.40 M |
$239.54 M |
$202.83 M |
| Interest Income |
$11.44 M |
$4.54 M |
$896,000.00 |
$4.63 M |
$7.38 M |
$6.50 M |
$4.08 M |
$1.32 M |
$678,000.00 |
$382,000.00 |
| Interest Expense |
$20.31 M |
$39.98 M |
$31.75 M |
$25.67 M |
$23.63 M |
$21.95 M |
$18.05 M |
$7.06 M |
$7.73 M |
$8.28 M |
| Depreciation &
Amortization |
$75.57 M
|
$91.50 M
|
$28.55 M
|
$19.91 M
|
$19.58 M
|
$13.17 M
|
$13.83 M
|
$12.92 M
|
$11.48 M
|
$10.04 M
|
| EBITDA |
$162.90 M
|
$144.78 M
|
$118.47 M
|
$71.42 M
|
$55.29 M
|
$33.06 M
|
-$10.59 M
|
-$17.86 M
|
$21.39 M
|
$5.09 M
|
| EBITDA Ratio |
0.24 |
0.18 |
0.27 |
0.16 |
0.1 |
0.07 |
-0.06 |
-0.11 |
0.04 |
-0.03 |
| Operating Income Ratio
|
0.13
|
0.09
|
0.24
|
0.11
|
0.09
|
0.05
|
-0.09
|
-0.12
|
0.04
|
-0.03
|
| Total Other
Income/Expenses Net |
-$25.97 M
|
-$46.72 M
|
-$33.52 M
|
-$26.26 M
|
-$26.66 M
|
-$16.34 M
|
-$17.53 M
|
-$5.82 M
|
-$7.34 M
|
-$8.38 M
|
| Income Before Tax |
$61.70 M |
$13.30 M |
$56.40 M |
$20.09 M |
-$10.75 M |
-$425,000.00 |
-$42.47 M |
-$37.84 M |
$2.12 M |
-$13.54 M |
| Income Before Tax Ratio
|
0.09
|
0.02
|
0.1
|
0.05
|
-0.03
|
-0
|
-0.15
|
-0.14
|
0.01
|
-0.07
|
| Income Tax Expense |
$19.75 M |
-$2.61 M |
$14.42 M |
-$125.43 M |
$268,000.00 |
$46,000.00 |
$140,000.00 |
$105,000.00 |
$264,000.00 |
$173,000.00 |
| Net Income |
$41.96 M |
$15.91 M |
$41.98 M |
$145.52 M |
-$11.02 M |
-$471,000.00 |
-$42.61 M |
-$37.95 M |
$1.86 M |
-$13.72 M |
| Net Income Ratio |
0.06 |
0.02 |
0.08 |
0.35 |
-0.03 |
-0 |
-0.15 |
-0.14 |
0.01 |
-0.07 |
| EPS |
0.91 |
0.35 |
0.95 |
3.41 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
0.05 |
-0.39 |
| EPS Diluted |
0.81 |
0.34 |
0.92 |
3.33 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
0.04 |
-0.39 |
| Weighted Average Shares
Out |
$46.22 M
|
$45.52 M
|
$44.26 M
|
$42.67 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.20 M
|
$36.54 M
|
$35.17 M
|
| Weighted Average Shares
Out Diluted |
$51.98 M
|
$46.54 M
|
$45.63 M
|
$43.68 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.24 M
|
$41.30 M
|
$35.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
